Literature DB >> 1859054

Combined APACHE II score and serum lactate dehydrogenase as predictors of in-hospital mortality caused by first episode Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome.

C A Benson1, J Spear, D Hines, J C Pottage, H A Kessler, G M Trenholme.   

Abstract

We retrospectively analyzed data from 75 hospitalized patients with a first episode of Pneumocystis carinii pneumonia to compare the ability of four parameters, including admission serum albumin, serum lactate dehydrogenase (LDH), alveolar-arterial oxygen gradient, and the APACHE II score, to predict mortality and response to initial antipneumocystis therapy. The eight patients who died due to pneumocystosis and the 12 who failed initial antipneumocystis therapy had significantly higher admission mean APACHE II scores and serum LDH levels and lower mean serum albumin levels than did the 65 who survived and the 61 who responded to initial therapy (p less than 0.05 for each). Differences in mean alveolar-arterial oxygen gradients were not statistically significant with respect to survival or response to initial therapy. In a stepwise discriminant analysis of parameters associated with mortality, APACHE II score and LDH level were statistically significant (p less than 0.0001 for each). In a stepwise discriminant analysis of parameters associated with response to initial therapy, APACHE II score and LDH level were again statistically significant (p less than 0.0001, respectively). The addition of the alveolar-arterial oxygen gradient and serum albumin level did not further increase the predictive ability of the discriminant analyses. When analyzed alone, neither the alveolar-arterial oxygen gradient nor the serum albumin were statistically significant in each discriminant analysis. The APACHE II score combined with the serum LDH may be more useful than other parameters, singly or combined, to more closely match patients with regard to severity of illness due to first episode Pneumocystis carinii pneumonia when comparing experimental new therapies with standard agents.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1859054     DOI: 10.1164/ajrccm/144.2.319

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  7 in total

1.  Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy.

Authors:  R F Miller; E Allen; A Copas; M Singer; S G Edwards
Journal:  Thorax       Date:  2006-04-06       Impact factor: 9.139

2.  Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort study.

Authors:  M W Fei; E J Kim; C A Sant; L G Jarlsberg; J L Davis; A Swartzman; L Huang
Journal:  Thorax       Date:  2009-10-12       Impact factor: 9.139

3.  Predicting in-hospital outcome in HIV-associated Pneumocystis carinii pneumonia.

Authors:  T Bauer; S Ewig; E Hasper; J K Rockstroh; B Lüderitz
Journal:  Infection       Date:  1995 Sep-Oct       Impact factor: 3.553

4.  Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006.

Authors:  Peter D Walzer; Hannah E R Evans; Andrew J Copas; Simon G Edwards; Alison D Grant; Robert F Miller
Journal:  Clin Infect Dis       Date:  2008-02-15       Impact factor: 9.079

5.  Quantitative competitive PCR with bronchoalveolar lavage fluid for diagnosis of toxoplasmosis in AIDS patients.

Authors:  S Bretagne; J M Costa; J Fleury-Feith; F Poron; M L Dubreuil-Lemaire; M Vidaud
Journal:  J Clin Microbiol       Date:  1995-06       Impact factor: 5.948

6.  Depletion of CD4 T cells provides therapeutic benefits in aged mice after ischemic stroke.

Authors:  Nia M Harris; Meaghan Roy-O'Reilly; Rodney M Ritzel; Aleah Holmes; Lauren H Sansing; Lena M O'Keefe; Louise D McCullough; Anjali Chauhan
Journal:  Exp Neurol       Date:  2020-01-15       Impact factor: 5.330

7.  Prognostic factors influencing the outcome in pneumocystis carinii pneumonia in patients with AIDS.

Authors:  P Fernandez; A Torres; J M Miro; C Vieigas; J Mallolas; L Zamora; J M Gatell; M E Valls; R Riquelme; R Rodríguez-Roisin
Journal:  Thorax       Date:  1995-06       Impact factor: 9.139

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.